Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Study Details
Study Description
Brief Summary
Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the population of patients who may be offered this therapy to those who are older and more infirmed. The field is now focusing on the period post transplant for approaches to immune recovery leading to improved outcomes.
The primary objective of this registry is to catalogue data from patients who undergo standard of care reduced intensity allogeneic transplantation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Subjects will have toxicity monitored and reported per the Center for International Blood and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone marrow transplant (BMT) reporting in the USA. Data will be collected from physical exam, laboratory studies, radiographs that are performed for clinical purposes. The tests and procedures are not in addition or in excess of our standards for allogeneic transplant outside of this registry. Data about donors will also be collected.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Reduced Intensity Allogeneic Transplant Subjects undergoing a reduced intensity allogeneic stem cell transplant |
Outcome Measures
Primary Outcome Measures
- Catalogue Data [1 year]
Catalogue data from subjects who undergo standard of care reduced intensity allogeneic transplantation.
Eligibility Criteria
Criteria
Recipient Inclusion Criteria:
- Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant
Exclusion Criteria:
-
Subjects < 18 years of age
-
Subjects not undergoing nonmyeloablative or ablative allogeneic transplant
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Duke University Health System | Durham | North Carolina | United States | 27710 |
Sponsors and Collaborators
- Duke University
Investigators
- Principal Investigator: David Rizzieri, MD, Duke Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00041936